Absci Has Initiated IND-enabling Studies For ABS-101 Using Absci's De Novo Generative AI Foundation Model; Absci Expects To Submit An IND For ABS-101 In First Quarter Of 2025
Portfolio Pulse from Benzinga Newsdesk
Absci has started IND-enabling studies for ABS-101, leveraging its De Novo Generative AI Foundation Model. The company plans to submit an IND for ABS-101 in the first quarter of 2025.
February 21, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Absci's initiation of IND-enabling studies for ABS-101, using its AI model, indicates progress in its pipeline, aiming for a Q1 2025 IND submission.
The initiation of IND-enabling studies for ABS-101 by Absci is a significant step in the drug development process, indicating progress in its pipeline. This move, leveraging their AI technology, could be seen positively by investors as it demonstrates the company's commitment to innovation and its potential for future growth. The planned IND submission by Q1 2025 sets a clear timeline for further development milestones.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100